Goldman Sachs
CALA

Goldman Sachs’s Calithera Biosciences, Inc CALA Stock Holding History

Goldman Sachs’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,187
Closed -$50K – 6913
2022
Q1 		$50K Buy
6,187
+3,643
+143% +$37.2K ﹤0.01% 6275
2021
Q4 		$34K Sell
2,544
-951
-27% -$23.9K ﹤0.01% 6317
2021
Q3 		$152K Sell
3,495
-6,670
-66% -$288K ﹤0.01% 5817
2021
Q2 		$425K Sell
10,165
-5,515
-35% -$242K ﹤0.01% 5305
2021
Q1 		$759K Buy
15,680
+9,167
+141% +$534K ﹤0.01% 4819
2020
Q4 		$639K Sell
6,513
-1,090
-14% -$95.5K ﹤0.01% 4464
2020
Q3 		$525K Sell
7,603
-186
-2% -$16.2K ﹤0.01% 4459
2020
Q2 		$823K Buy
7,789
+1,971
+34% +$234K ﹤0.01% 4086
2020
Q1 		$517K Sell
5,818
-961
-14% -$114K ﹤0.01% 4196
2019
Q4 		$774K Buy
6,779
+958
+16% +$72.1K ﹤0.01% 4274
2019
Q3 		$360K Sell
5,821
-3,089
-35% -$247K ﹤0.01% 4605
2019
Q2 		$695K Buy
8,910
+2,173
+32% +$247K ﹤0.01% 4225
2019
Q1 		$908K Buy
6,737
+15
+0.2% +$1.58K ﹤0.01% 4112
2018
Q4 		$539K Buy
6,722
+2,652
+65% +$262K ﹤0.01% 4324
2018
Q3 		$427K Sell
4,070
-1,473
-27% -$140K ﹤0.01% 4501
2018
Q2 		$554K Sell
5,543
-3,893
-41% -$441K ﹤0.01% 4449
2018
Q1 		$1.19M Buy
9,436
+1,068
+13% +$167K ﹤0.01% 3940
2017
Q4 		$1.4M Buy
8,368
+1,443
+21% +$370K ﹤0.01% 4071
2017
Q3 		$2.18M Buy
6,925
+466
+7% +$147K ﹤0.01% 3907
2017
Q2 		$1.92M Sell
6,459
-240
-4% -$64.2K ﹤0.01% 3874
2017
Q1 		$1.55M Buy
6,699
+5,892
+730% +$1.02M ﹤0.01% 3999
2016
Q4 		$52K Buy
807
+258
+47% +$16.1K ﹤0.01% 6379
2016
Q3 		$36K Sell
549
-674
-55% -$43.5K ﹤0.01% 6587
2016
Q2 		$91K Buy
+1,223
New +$122K ﹤0.01% 6177
2015
Q3 		– Sell
-1,179
Closed -$168K – 7554
2015
Q2 		$168K Buy
+1,179
New +$273K ﹤0.01% 6277

Other funds holding CALA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's CALA Position: Q2 2022 in Review

Goldman Sachs sold out of Calithera Biosciences, Inc (CALA) in Q2 2022, closing a stake of 6,187 shares — an estimated $50K sold.

Goldman Sachs first reported a position in CALA in Q2 2015 and held it in 25 quarters. The position peaked at $2.18M in Q3 2017. 28 funds tracked by Wall St. Rank hold CALA as of Q2 2022.

  • Goldman Sachs reported no remaining Calithera Biosciences, Inc position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 6,187 Calithera Biosciences, Inc shares in Q2 2022, an estimated $50K.
  • Goldman Sachs first reported a position in Calithera Biosciences, Inc in Q2 2015 and held it in 25 quarters.
  • Goldman Sachs's Calithera Biosciences, Inc position peaked at $2.18M in Q3 2017.
  • 28 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.